Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Neutrophil activation cause of inflammation in canine liver disease
Liver disease is a major health issue in dogs.
Research links high ammonia levels to immune response and inflammation

The Royal (Dick) School of Veterinary Medicine and The Roslin Institute have discovered that high levels of ammonia in dogs with liver disease causes an unregulated immune response by activating neutrophils. The resultant inflammation seen in these cases then further decreases the dog’s overall health.

Inflammatory molecules and high levels of ammonia are commonly discovered in canine liver disease cases and, while treating the liver disease generally results in a decrease in both ammonia and inflammation levels, it has not been known until now what caused the associated inflammation.

Inflammation is a natural and often useful immune response when infection is present, but it is thought that when this response is activated inappropriately, that significant detriment can occur within the body.

Craig R. Breheny, lead scientist involved in the research, states: “Liver disease is a huge issue both in human and veterinary medicine. This study shows how the relationship between ammonia and the inflammatory response strengthens the dog’s role as a model of the human condition”.

Treatment for liver disease is often supportive and the aetiology is largely unknown.

By closely observing the precise activity of these neutrophils, the researchers hope to develop improved treatment and to prevent this unregulated immune response. Breheny concludes: “By understanding how the disease works, new therapies can be investigated to the benefit of both veterinary and human patients”.

 

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'